Fostamatinib’s mechanism of action

Fostamatinib (fostamatinib) is an oral thrombocytopenia treatment drug. Its mechanism of action is based on inhibiting the kinase signaling pathway in the body, especially the activity of Syk kinase, thereby achieving the purpose of increasing the number of platelets. It is the world's first and only approved oral spleen tyrosine kinase (SYK) inhibitor and has significant efficacy in chronic immune thrombocytopenia (ITP).

Fostatinib tablets are formulated as fostatinib disodium hexahydrate, a disodium hexahydrate salt that is a prodrug of the active compound tamatinib (R-406), which is an inhibitor of spleen tyrosine kinase (Syk), and is therefore a syk inhibitor.

Syk is a protein tyrosine kinase associated with various inflammatory cells, including macrophages, the cells thought to be responsible for platelet clearance of ITP. When FcγRs I, IIA, and IIIA bind to their ligands, the receptor complex is activated and triggers phosphorylation of the immunoreceptor activation motif (ITAM). This results in the activation of various genes that cause cytoskeletal rearrangements that mediate phagocytosis by cells of the monocyte/macrophage lineage. Because Syk plays an important role in FcγR-mediated signal transduction and inflammation propagation, it is considered a good target for the suppression of various autoimmune diseases, including rheumatoid arthritis and lymphoma.

In general, fostatinib inhibitsSyk kinase activity, reduces platelet destruction and promotes the generation of new platelets, thereby effectively increasing the number of platelets and improving the symptoms of ITP patients. Its unique mechanism of action and good safety make fostatinib occupy an important position in the treatment of thrombocytopenia.